Eisai launches cancer drug Lenvatinib in Mexico
pharmafile | July 4, 2016 | News story | Research and Development, Sales and Marketing | Cancer, Eisai, Mexico, lenvatinib, product launch
Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico.
Lenvima is a molecular targeted agent with a novel binding mode. The drug is approved as a treatment for refractory thyroid cancer in over 40 countries including the US, Japan, Europe, South Korea and Canada.
In Mexico, the drug was approved for treatment of differentiated thyroid cancer in May 2016.
In 2014, Mexico’s pharmaceutical market was worth $11.3 billion, the 16th biggest in the world, and the third largest in Latin America after Brazil and Venezuela. In 2019, Mexico’s pharmaceutical market is expected to grow to $13.4 billion.
In August 2011, Eisai set up its unit in Mexico, which currently markets the anticancer agents Halaven and Gliadel in addition to Lenvima.
In May 2016, Lenvima was also approved for an additional indication in the US in combination with everolimus for the treatment of advanced renal cell carcinoma. A new drug application seeking approval for an indication covering advanced or metastatic renal cell carcinoma has been submitted in Europe in January 2016.
Eisai is also conducting clinical studies of Lenvima in several other tumor types such as hepatocellular carcinoma (Phase III), endometrial carcinoma (Phase II), biliary tract cancer (Phase II), and in combination with an immune checkpoint inhibitor (Phase Ib/II).
Anjali Shukla
Related Content
Baxter expands US portfolio with new injectables
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …